{"id":494146,"date":"2021-05-17T08:07:44","date_gmt":"2021-05-17T12:07:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-launches-its-not-ok-its-td-national-television-advertising-campaign-to-increase-awareness-of-tardive-dyskinesia-and-austedo-deutetrabenazine-tablets\/"},"modified":"2021-05-17T08:07:44","modified_gmt":"2021-05-17T12:07:44","slug":"teva-launches-its-not-ok-its-td-national-television-advertising-campaign-to-increase-awareness-of-tardive-dyskinesia-and-austedo-deutetrabenazine-tablets","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/teva-launches-its-not-ok-its-td-national-television-advertising-campaign-to-increase-awareness-of-tardive-dyskinesia-and-austedo-deutetrabenazine-tablets\/","title":{"rendered":"Teva Launches ‘It’s Not OK – It’s TD’ National Television Advertising Campaign to Increase Awareness of Tardive Dyskinesia and AUSTEDO\u00ae (deutetrabenazine) tablets"},"content":{"rendered":"
\n

Campaign kicks off during Mental Health Awareness Month and on the heels of Tardive Dyskinesia (TD) Week<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n TEL AVIV<\/span>, Israel\u00a0and PARSIPPANY, N.J.<\/span>, May 17, 2021<\/span> \/PRNewswire\/ —\u00a0Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) (TASE: TEVA), today announced the launch of It’s Not OK \u2013 It’s TD<\/i>, a new national television advertising campaign, which aims to inspire patients with tardive dyskinesia (TD) symptoms to speak up and share the impact of TD with their healthcare provider, start working together to manage their symptoms rather than coping, and ask about how treatment with AUSTEDO\u00ae<\/sup> (deutetrabenazine) tablets may help. Encouraging patients to say, ‘It’s not OK,’ the ad drives awareness of AUSTEDO, a prescription medicine that may help manage TD while patients continue their mental health medication(s)\u00a0like antipsychotics or antidepressants.\u00a0 <\/p>\n

\n

\n
\n \"Teva
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Tardive dyskinesia is associated with certain prescription medicines used to treat mental health or gastrointestinal conditions.1,2<\/sup> One in four people who take certain mental health treatments may develop the uncontrollable movements of TD, including mild-to-severe twitching, shaking or jerking of hands, feet, face or torso, and more. Whether symptoms are mild, moderate, or severe, the impact of TD can be significant, causing physical changes that may lead to functional and emotional changes.1<\/sup>,<\/sup>2<\/sup>,3<\/sup>\u00a0<\/p>\n

“As we navigate through a global pandemic, we know there is an increase in individuals reporting symptoms of anxiety or depressive disorder,” said Brendan O’Grady<\/span>, Executive Vice President and Head of North America Commercial at Teva. “Now more than ever, it is important to elevate our efforts to support individuals with TD and mental health conditions. We developed the ‘It’s Not OK \u2013 It’s TD’ campaign based on valuable insights from patients with TD, allowing us to put a much needed and authentic spotlight on the disorder and how it can truly impact well-being, while driving education about AUSTEDO as a treatment that may help manage their TD symptoms.”\u00a0\u00a0 <\/p>\n

People living with mental health conditions often feel stigmatized and delay seeking treatment.4<\/sup> For some patients, finding the right combination of mental health medications can take several years, and some living with TD would rather cope with their movements than alter their existing treatment regimen and risk relapse.5<\/sup>,6,7<\/sup><\/p>\n

“TD is already under-diagnosed and under-treated, and with increasing telemedicine visits, it is more challenging to visually identify TD movements, leaving patients to continue coping with the physical and emotional impact of their symptoms,” said Rakesh Jain<\/span>, MD, MPH, Clinical Professor, Department of Psychiatry, Texas Tech Health Sciences Center School of Medicine, Midland. “For patients with mental health conditions, it’s critical that we initiate open discussions about their experience with TD and in managing it, we don’t take away from their progress and related treatment plan. I’m pleased AUSTEDO can help patients manage their TD symptoms without affecting their mental health treatment regimens.”<\/p>\n

In one clinical study, AUSTEDO significantly reduced the involuntary movements of TD after 12 weeks of treatment vs. placebo, with improvement beginning to be seen as early as 2 weeks. Additionally, in an open label extension study\u2014the longest TD study to date\u2014symptom control was sustained through 145 weeks, and no new adverse events were observed compared to those in pivotal trials. The most common side effects of AUSTEDO include inflammation of the nose and throat (nasopharyngitis) and problems sleeping (insomnia).8<\/sup>,9,10 <\/sup><\/p>\n

Several informational resources are available on AUSTEDO.com to help individuals throughout the entire process\u2014from learning more about TD to starting and staying on course with treatment: <\/p>\n